José Baselga heads oncology R&D at AstraZeneca. His longstanding research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 450 peer-reviewed publications to date. He conducted pivotal laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab and everolimus, among other therapies. His current work is in targeting PI3K and deciphering mechanisms of resistance to anti-estrogen therapies.
José most recently served as physician-in-chief at Memorial Sloan Kettering Cancer Center. Prior to that, he was also the chairman of medical oncology and founding director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. José is a past president of the American Association of Cancer Research (AACR), a past president of the European Society for Medical Oncology (ESMO) and a past member of the board of directors for the American Society of Clinical Oncology. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians and a Fellow of the AACR Academy. He is a past member of the editorial boards of Cancer Cell, Journal of Clinical Oncology and Clinical Cancer Research and served as the founding editor-in-chief for the AACR flagship journal, Cancer Discovery.